Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 9217 to 9224 of 9224 entries
Sorted by: Best Match Show Resources per page
Inflammatory Cell Composition and Immune-Related microRNA Signature of Temporal Artery Biopsies From Patients With Giant Cell Arteritis.

Frontiers in immunology

Bolha L, Hočevar A, Suljič A, Jurčić V.
PMID: 35003111
Front Immunol. 2021 Dec 23;12:791099. doi: 10.3389/fimmu.2021.791099. eCollection 2021.

OBJECTIVES: The aim of this study was to quantitatively assess distinct immune cell subsets comprising inflammatory infiltrate in temporal artery biopsies (TABs) from patients with giant cell arteritis (GCA), and to link the obtained histopathological data with expression profiles...

Cite
Bolha L, Hočevar A, Suljič A, et al. Inflammatory Cell Composition and Immune-Related microRNA Signature of Temporal Artery Biopsies From Patients With Giant Cell Arteritis. Front Immunol. 2021;12:791099doi: 10.3389/fimmu.2021.791099.
Bolha, L., Hočevar, A., Suljič, A., & Jurčić, V. (2021). Inflammatory Cell Composition and Immune-Related microRNA Signature of Temporal Artery Biopsies From Patients With Giant Cell Arteritis. Frontiers in immunology, 12791099. https://doi.org/10.3389/fimmu.2021.791099
Bolha, Luka, et al. "Inflammatory Cell Composition and Immune-Related microRNA Signature of Temporal Artery Biopsies From Patients With Giant Cell Arteritis." Frontiers in immunology vol. 12 (2021): 791099. doi: https://doi.org/10.3389/fimmu.2021.791099
Bolha L, Hočevar A, Suljič A, Jurčić V. Inflammatory Cell Composition and Immune-Related microRNA Signature of Temporal Artery Biopsies From Patients With Giant Cell Arteritis. Front Immunol. 2021 Dec 23;12:791099. doi: 10.3389/fimmu.2021.791099. eCollection 2021. PMID: 35003111; PMCID: PMC8733475.
Copy Download .nbib Format: NLM
Targeting TREM2 for Parkinson's Disease: Where to Go?.

Frontiers in immunology

Li XX, Zhang F.
PMID: 35003116
Front Immunol. 2021 Dec 24;12:795036. doi: 10.3389/fimmu.2021.795036. eCollection 2021.

Parkinson's disease (PD) is one of most common neurodegenerative disorders caused by a combination of environmental and genetic risk factors. Currently, numerous population genetic studies have shown that polymorphisms in myeloid cell-triggered receptor II (TREM2) are associated with a...

Cite
Li XX, Zhang F. Targeting TREM2 for Parkinson's Disease: Where to Go?. Front Immunol. 2021;12:795036doi: 10.3389/fimmu.2021.795036.
Li, X. X., & Zhang, F. (2021). Targeting TREM2 for Parkinson's Disease: Where to Go?. Frontiers in immunology, 12795036. https://doi.org/10.3389/fimmu.2021.795036
Li, Xiao-Xian, and Zhang, Feng. "Targeting TREM2 for Parkinson's Disease: Where to Go?." Frontiers in immunology vol. 12 (2021): 795036. doi: https://doi.org/10.3389/fimmu.2021.795036
Li XX, Zhang F. Targeting TREM2 for Parkinson's Disease: Where to Go?. Front Immunol. 2021 Dec 24;12:795036. doi: 10.3389/fimmu.2021.795036. eCollection 2021. PMID: 35003116; PMCID: PMC8740229.
Copy Download .nbib Format: NLM
The Immunological Impact of IL-1 Family Cytokines on the Epidermal Barrier.

Frontiers in immunology

Macleod T, Berekmeri A, Bridgewood C, Stacey M, McGonagle D, Wittmann M.
PMID: 35003136
Front Immunol. 2021 Dec 23;12:808012. doi: 10.3389/fimmu.2021.808012. eCollection 2021.

The skin barrier would not function without IL-1 family members, but their physiological role in the immunological aspects of skin barrier function are often overlooked. This review summarises the role of IL-1 family cytokines (IL-1α, IL-1β, IL-1Ra, IL-18, IL-33,...

Cite
Macleod T, Berekmeri A, Bridgewood C, et al. The Immunological Impact of IL-1 Family Cytokines on the Epidermal Barrier. Front Immunol. 2021;12:808012doi: 10.3389/fimmu.2021.808012.
Macleod, T., Berekmeri, A., Bridgewood, C., Stacey, M., McGonagle, D., & Wittmann, M. (2021). The Immunological Impact of IL-1 Family Cytokines on the Epidermal Barrier. Frontiers in immunology, 12808012. https://doi.org/10.3389/fimmu.2021.808012
Macleod, Tom, et al. "The Immunological Impact of IL-1 Family Cytokines on the Epidermal Barrier." Frontiers in immunology vol. 12 (2021): 808012. doi: https://doi.org/10.3389/fimmu.2021.808012
Macleod T, Berekmeri A, Bridgewood C, Stacey M, McGonagle D, Wittmann M. The Immunological Impact of IL-1 Family Cytokines on the Epidermal Barrier. Front Immunol. 2021 Dec 23;12:808012. doi: 10.3389/fimmu.2021.808012. eCollection 2021. PMID: 35003136; PMCID: PMC8733307.
Copy Download .nbib Format: NLM
Primary Immunodeficiencies: A Decade of Progress and a Promising Future.

Frontiers in immunology

Meyts I, Bousfiha A, Duff C, Singh S, Lau YL, Condino-Neto A, Bezrodnik L, Ali A, Adeli M, Drabwell J.
PMID: 33679719
Front Immunol. 2021 Feb 18;11:625753. doi: 10.3389/fimmu.2020.625753. eCollection 2020.

No abstract available.

Cite
Meyts I, Bousfiha A, Duff C, et al. Primary Immunodeficiencies: A Decade of Progress and a Promising Future. Front Immunol. 2021;11:625753doi: 10.3389/fimmu.2020.625753.
Meyts, I., Bousfiha, A., Duff, C., Singh, S., Lau, Y. L., Condino-Neto, A., Bezrodnik, L., Ali, A., Adeli, M., & Drabwell, J. (2020). Primary Immunodeficiencies: A Decade of Progress and a Promising Future. Frontiers in immunology, 11625753. https://doi.org/10.3389/fimmu.2020.625753
Meyts, Isabelle, et al. "Primary Immunodeficiencies: A Decade of Progress and a Promising Future." Frontiers in immunology vol. 11 (2020): 625753. doi: https://doi.org/10.3389/fimmu.2020.625753
Meyts I, Bousfiha A, Duff C, Singh S, Lau YL, Condino-Neto A, Bezrodnik L, Ali A, Adeli M, Drabwell J. Primary Immunodeficiencies: A Decade of Progress and a Promising Future. Front Immunol. 2021 Feb 18;11:625753. doi: 10.3389/fimmu.2020.625753. eCollection 2020. PMID: 33679719; PMCID: PMC7935502.
Copy Download .nbib Format: NLM
Editorial: The Role of Metabolism in MSC-Mediated Immunomodulation.

Frontiers in immunology

Pers YM, Jorgensen C, Khoury M.
PMID: 34512675
Front Immunol. 2021 Aug 26;12:751865. doi: 10.3389/fimmu.2021.751865. eCollection 2021.

No abstract available.

Cite
Pers YM, Jorgensen C, Khoury M. Editorial: The Role of Metabolism in MSC-Mediated Immunomodulation. Front Immunol. 2021;12:751865doi: 10.3389/fimmu.2021.751865.
Pers, Y. M., Jorgensen, C., & Khoury, M. (2021). Editorial: The Role of Metabolism in MSC-Mediated Immunomodulation. Frontiers in immunology, 12751865. https://doi.org/10.3389/fimmu.2021.751865
Pers, Yves-Marie, et al. "Editorial: The Role of Metabolism in MSC-Mediated Immunomodulation." Frontiers in immunology vol. 12 (2021): 751865. doi: https://doi.org/10.3389/fimmu.2021.751865
Pers YM, Jorgensen C, Khoury M. Editorial: The Role of Metabolism in MSC-Mediated Immunomodulation. Front Immunol. 2021 Aug 26;12:751865. doi: 10.3389/fimmu.2021.751865. eCollection 2021. PMID: 34512675; PMCID: PMC8426546.
Copy Download .nbib Format: NLM
Machine Learning Approaches in Study of Multiple Sclerosis Disease Through Magnetic Resonance Images.

Frontiers in immunology

Moazami F, Lefevre-Utile A, Papaloukas C, Soumelis V.
PMID: 34456913
Front Immunol. 2021 Aug 11;12:700582. doi: 10.3389/fimmu.2021.700582. eCollection 2021.

Multiple sclerosis (MS) is one of the most common autoimmune diseases which is commonly diagnosed and monitored using magnetic resonance imaging (MRI) with a combination of clinical manifestations. The purpose of this review is to highlight the main applications...

Cite
Moazami F, Lefevre-Utile A, Papaloukas C, et al. Machine Learning Approaches in Study of Multiple Sclerosis Disease Through Magnetic Resonance Images. Front Immunol. 2021;12:700582doi: 10.3389/fimmu.2021.700582.
Moazami, F., Lefevre-Utile, A., Papaloukas, C., & Soumelis, V. (2021). Machine Learning Approaches in Study of Multiple Sclerosis Disease Through Magnetic Resonance Images. Frontiers in immunology, 12700582. https://doi.org/10.3389/fimmu.2021.700582
Moazami, Faezeh, et al. "Machine Learning Approaches in Study of Multiple Sclerosis Disease Through Magnetic Resonance Images." Frontiers in immunology vol. 12 (2021): 700582. doi: https://doi.org/10.3389/fimmu.2021.700582
Moazami F, Lefevre-Utile A, Papaloukas C, Soumelis V. Machine Learning Approaches in Study of Multiple Sclerosis Disease Through Magnetic Resonance Images. Front Immunol. 2021 Aug 11;12:700582. doi: 10.3389/fimmu.2021.700582. eCollection 2021. PMID: 34456913; PMCID: PMC8385534.
Copy Download .nbib Format: NLM
Interferon-Induced Transmembrane Protein 3 Shapes an Inflamed Tumor Microenvironment and Identifies Immuno-Hot Tumors.

Frontiers in immunology

Cai Y, Ji W, Sun C, Xu R, Chen X, Deng Y, Pan J, Yang J, Zhu H, Mei J.
PMID: 34456915
Front Immunol. 2021 Aug 11;12:704965. doi: 10.3389/fimmu.2021.704965. eCollection 2021.

Interferon-induced transmembrane protein 3 (IFITM3) is an interferon-induced membrane protein, which has been identified as a functional gene in multiple human cancers. The role of IFITM3 in cancer has been preliminarily summarized, but its relationship to antitumor immunity is...

Cite
Cai Y, Ji W, Sun C, et al. Interferon-Induced Transmembrane Protein 3 Shapes an Inflamed Tumor Microenvironment and Identifies Immuno-Hot Tumors. Front Immunol. 2021;12:704965doi: 10.3389/fimmu.2021.704965.
Cai, Y., Ji, W., Sun, C., Xu, R., Chen, X., Deng, Y., Pan, J., Yang, J., Zhu, H., & Mei, J. (2021). Interferon-Induced Transmembrane Protein 3 Shapes an Inflamed Tumor Microenvironment and Identifies Immuno-Hot Tumors. Frontiers in immunology, 12704965. https://doi.org/10.3389/fimmu.2021.704965
Cai, Yun, et al. "Interferon-Induced Transmembrane Protein 3 Shapes an Inflamed Tumor Microenvironment and Identifies Immuno-Hot Tumors." Frontiers in immunology vol. 12 (2021): 704965. doi: https://doi.org/10.3389/fimmu.2021.704965
Cai Y, Ji W, Sun C, Xu R, Chen X, Deng Y, Pan J, Yang J, Zhu H, Mei J. Interferon-Induced Transmembrane Protein 3 Shapes an Inflamed Tumor Microenvironment and Identifies Immuno-Hot Tumors. Front Immunol. 2021 Aug 11;12:704965. doi: 10.3389/fimmu.2021.704965. eCollection 2021. PMID: 34456915; PMCID: PMC8385493.
Copy Download .nbib Format: NLM
Coadministration of Anti-Viral Monoclonal Antibodies With Routine Pediatric Vaccines and Implications for Nirsevimab Use: A White Paper.

Frontiers in immunology

Esposito S, Abu-Raya B, Bonanni P, Cahn-Sellem F, Flanagan KL, Martinon Torres F, Mejias A, Nadel S, Safadi MAP, Simon A.
PMID: 34456918
Front Immunol. 2021 Aug 11;12:708939. doi: 10.3389/fimmu.2021.708939. eCollection 2021.

Routine childhood vaccinations are key for the protection of children from a variety of serious and potentially fatal diseases. Current pediatric vaccine schedules mainly cover active vaccines. Active vaccination in infants is a highly effective approach against several infectious...

Cite
Esposito S, Abu-Raya B, Bonanni P, et al. Coadministration of Anti-Viral Monoclonal Antibodies With Routine Pediatric Vaccines and Implications for Nirsevimab Use: A White Paper. Front Immunol. 2021;12:708939doi: 10.3389/fimmu.2021.708939.
Esposito, S., Abu-Raya, B., Bonanni, P., Cahn-Sellem, F., Flanagan, K. L., Martinon Torres, F., Mejias, A., Nadel, S., Safadi, M. A. P., & Simon, A. (2021). Coadministration of Anti-Viral Monoclonal Antibodies With Routine Pediatric Vaccines and Implications for Nirsevimab Use: A White Paper. Frontiers in immunology, 12708939. https://doi.org/10.3389/fimmu.2021.708939
Esposito, Susanna, et al. "Coadministration of Anti-Viral Monoclonal Antibodies With Routine Pediatric Vaccines and Implications for Nirsevimab Use: A White Paper." Frontiers in immunology vol. 12 (2021): 708939. doi: https://doi.org/10.3389/fimmu.2021.708939
Esposito S, Abu-Raya B, Bonanni P, Cahn-Sellem F, Flanagan KL, Martinon Torres F, Mejias A, Nadel S, Safadi MAP, Simon A. Coadministration of Anti-Viral Monoclonal Antibodies With Routine Pediatric Vaccines and Implications for Nirsevimab Use: A White Paper. Front Immunol. 2021 Aug 11;12:708939. doi: 10.3389/fimmu.2021.708939. eCollection 2021. PMID: 34456918; PMCID: PMC8386277.
Copy Download .nbib Format: NLM
Showing 9217 to 9224 of 9224 entries